Clinical Trials | malecare.org

The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]

By Malecare|2020-02-04T11:37:24-05:00May 22nd, 2015|Advanced Prostate Cancer, Bones and Prostate Cancer, Clinical Trials, enzalutamide, Quality of Life, survival, Uncategorized, Xtandi|0 Comments

More People Surviving Cancer, But There Remains Groups That Have Not Had A Benefit

The good news is that many more people are surviving years after a cancer diagnosis. According to a new analysis the proportion of people surviving cancer is increasing through out the United States. The analysis showed that for both men and women aged 50 to 64 who were diagnosed between 2005 to 2009 with a [...]

By Malecare|2015-04-28T12:02:58-04:00April 28th, 2015|Advanced Prostate Cancer, Clinical Trials, Research, Uncategorized|0 Comments

Understanding How Personalized Medicine Is Developed By Way Of A Real Situation – Olaparib

It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer. These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job [...]

By Malecare|2021-04-29T10:07:31-04:00April 24th, 2015|Advanced Prostate Cancer, Clinical Trials, Drugs & Treatments, genetics, Inhibitors, olaparnib, PARP inhibitors, Research, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales|2 Comments

Updated Overall Survival Data from a Phase 3 Trial of Ipilimumab vs. Placebo in Men Post Chemotherapy Receiving Radiation Therapy – Still Needs Time

Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]

By Malecare|2015-04-14T10:41:35-04:00April 14th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, immunotherapy, ipilimumab, Radiotherapy, survival, Uncategorized, vaccines|0 Comments

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]

By Malecare|2020-02-04T11:45:03-05:00April 9th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, survival, Tasquinimod (TASQ), Uncategorized|1 Comment